Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03437070
Other study ID # 20170991
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date June 2019
Est. completion date June 2023

Study information

Verified date March 2019
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D) and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options.


Description:

This is a traditional 3+3 phase I trial design to identify the recommended phase II dose (RP2D) of Trabectedin [T] that can be used in combination with Doxorubicin [D] and Olaratumab [O] for the treatment of patients with advanced stage or recurrent LMS.

Patients will be treated at an assigned dose level of combination therapy per dose escalation design.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2023
Est. primary completion date June 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Histologically confirmed metastatic, advanced, or recurrent, LMS. Note: Patients should have tissue, either archival or fresh biopsy, submitted for pathologic review to confirm diagnosis of LMS. For patients with recurrent disease with disease free interval greater than six months, a fresh biopsy must be obtained.

2. All patients with recurrent or metastatic LMS deemed unresectable must have measurable disease as defined by RECIST 1.1.

All patients with advanced LMS may be enrolled after an initial cytoreductive surgery if there is measurable disease as defined by RECIST 1.1.

3. Life expectancy greater than 3 months.

4. Male or female, age =18 years

5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1.

6. Resolution of clinically significant toxic effects of prior surgery, radiotherapy or systemic anticancer therapy.

7. Patients must not have received prior doxorubicin chemotherapy; only 1 prior chemotherapy line allowable and must be discontinued at least 4 weeks prior to first day of study treatment.

8. Patients should be free of active infections requiring antibiotics (with exception of urinary tract infection).

9. Patients must have adequate organ and marrow function as defined below: Absolute neutrophil count (ANC) =1,500 cells/mm³

- Platelet count =100,000/mm³

- Hemoglobin =9.0g/dL

- Total bilirubin <1.0 upper limit of normal (ULN)

- Alkaline phosphatase of non-osseous origin = 2.5 x ULN

- Aminotransferase (AST and ALT) = 2.5 x ULN

- Creatinine phosphokinase (CPK) = 2.5 x ULN

- Isotope Dilution Mass Spectrometry (IDMS) creatinine = 1.5 x ULN or creatinine clearance = 40 mL/min

- Albumin = 3 g/dL*

- *Hypoalbuminemia < 3 g/dL should be considered carefully but in and of itself, not exclusionary.

10. Women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until 3 months for women and 5 months for men after completion of study drug administration. WOCBP must have a negative serum or urine test at time of enrollment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study therapy, and 5 months after completion of study drug administration.

11. Patients must have adequate cardiac function (ejection fraction = 45%) to receive therapy.

12. Ability to understand the investigational nature, potential risks and benefits of the research study and to provide valid written informed consent.

Exclusion Criteria:

1. Patients without histologically confirmed LMS

2. Patients without measurable disease by RECIST 1.1 criteria

3. Prior doxorubicin, trabectedin, or olaratumab chemotherapy

4. Patients with an ECOG of 2, 3 or 4 (Appendix C)

5. Patient with known allergies to pegfilgrastim/filgrastim.

6. Patients with known active central nervous system (CNS) metastasis and/or carcinomatous meningitis.

7. Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study therapy and during the study.

8. Patients with a known sensitivity to humanized antibodies or sensitivity attributed to compounds of similar chemical or biological composition to alkylating agents or anthracyclines.

9. A QT interval corrected for heart rate using the Bazett's formula (QTcB) = 480 msec.

10. Patients on combination antiretroviral therapy are ineligible.

11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infections (including viral hepatitis), decompensated cirrhosis or chronic liver disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.

12. Adults unable to consent, pregnant or nursing women or prisoners.

13. Any serious medical or psychiatric illness/condition likely in the judgment of the Investigator(s) to interfere or limit compliance with study requirements/treatment.

14. Diagnosis of another primary malignancy within the past 5 years with the exception of non-melanoma skin cancer.

15. Patients with a prior history of grade 3 capillary leak syndrome (CLS) or <grade 3 CLS with pulmonary involvement.

16. Unwilling to abstain from alcohol ingestion for duration of the study

17. Patients with elevated liver function or bilirubin not meeting criteria for treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Trabectedin
Administered intravenously per protocol on Day 1 for 21-day cycles.
Doxorubicin
Administered intravenously per protocol on Day 1 for 21-day cycles.
Olaratumab
Administered intravenously per protocol

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Miami Janssen Scientific Affairs, LLC

Outcome

Type Measure Description Time frame Safety issue
Primary Recommended Phase 2 Dose (RP2D) of Trabectedin in Combination with Doxorubucin and Olaratumab Determination of the recommended phase 2 dose (RP2D) of Trabectedin [T] to be used in combination with Doxorubicin [D] and Olaratumab [O] for the treatment of patients with metastatic or recurrent LMS. Patients will be treated at one of 4-6 dose levels according to the standard dose escalation/de-escalation scheme. In accordance with this scheme, the RP2D of TDO will be established as the highest dose level tested for which no more than 2 out of 12 patients experiences dose-limiting toxicity (DLT). About 21 days, one cycle of protocol therapy
Secondary Toxicity in Study Participants Determination of the safety, tolerability, and toxicity profile of administering TDO in metastatic or recurrent LMS patients, including assessment of dose-limiting toxicities (DLTs). Up to 8 months
Secondary Clinical Benefit Rate in Study Participants Clinical benefit rate (CBR), as defined by best response, (Complete Response (CR), Partial Response (PR) or Stable Disease (SD)) will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. From Baseline to End of Treatment, up to 8 months
See also
  Status Clinical Trial Phase
Recruiting NCT04535271 - Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma Phase 2
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT06088290 - Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma Phase 2/Phase 3
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Terminated NCT02940041 - Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
Completed NCT01442662 - Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine Phase 2
Completed NCT00062868 - LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma Phase 1
Recruiting NCT04214457 - Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
Active, not recruiting NCT04420975 - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Phase 1
Terminated NCT04099277 - A Study of LY3435151 in Participants With Solid Tumors Phase 1
Not yet recruiting NCT05548179 - Exploring Clinical Trial Experiences of People With Leiomyosarcoma
Recruiting NCT02983539 - Detection of Circulating Tumor Cells in Patients With Sarcomas
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Active, not recruiting NCT04624178 - A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma Phase 2
Terminated NCT03959033 - Patient Reported Outcome Measures (PROMs) With Trabectedin
Recruiting NCT02275286 - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Phase 1/Phase 2
Active, not recruiting NCT01956084 - Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma Phase 1
Completed NCT01426633 - Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas Phase 1
Completed NCT00400569 - Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Phase 2
Recruiting NCT05080790 - Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma Phase 2